- Home
- CRAC vs LRMR Comparison
CRAC vs LRMR Comparison
Compare CRAC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAC | LRMR |
|---|---|---|
| Founded | 2025 | N/A |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.7M | 253.5M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRAC | LRMR |
|---|---|---|
| Price | $10.28 | $2.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $14.40 |
| AVG Volume (30 Days) | 43.0K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $1.92 |
| 52 Week High | $10.30 | $6.42 |
Technical Indicators
Market Signals| Indicator | CRAC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 65.06 | 46.96 |
| Support Level | $10.18 | $1.92 |
| Resistance Level | N/A | $3.76 |
| Average True Range (ATR) | 0.01 | 0.22 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 60.00 | 76.69 |
Price Performance
Historical ComparisonAbout CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.